Cargando…

Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study

SIMPLE SUMMARY: The advent of immune checkpoint inhibitors (ICI) improved the prognosis for patients with advanced melanoma. However, many patients do not benefit from ICI therapy due to primary and acquired resistance. Observations in murine systems suggested that coagulation factor Xa impedes anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haist, Maximilian, Stege, Henner, Pemler, Saskia, Heinz, Jaqueline, Fleischer, Maria Isabel, Graf, Claudine, Ruf, Wolfram, Loquai, Carmen, Grabbe, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534137/ https://www.ncbi.nlm.nih.gov/pubmed/34680252 http://dx.doi.org/10.3390/cancers13205103

Ejemplares similares

The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges
por: Stege, Henner, et al.
Publicado: (2021)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
por: Haist, Maximilian, et al.
Publicado: (2022)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
por: Haist, Maximilian, et al.
Publicado: (2021)

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study
por: Stege, H. M., et al.
Publicado: (2021)

Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
por: Kuske, Michael, et al.
Publicado: (2022)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

Roles of factor Xa beyond coagulation
por: Ruf, Wolfram
Publicado: (2021)

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study
por: Mayer, Arnulf, et al.
Publicado: (2020)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients
por: Milling, Truman J., et al.
Publicado: (2021)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

eHealth Literacy in German Skin Cancer Patients
por: Stege, Henner, et al.
Publicado: (2022)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Effect of anticoagulants on fibrin clot structure: A comparison between vitamin K antagonists and factor Xa inhibitors
por: Gauer, Julia S., et al.
Publicado: (2020)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
por: Remko, Milan, et al.
Publicado: (2016)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease
por: Bednarczyk, Monika, et al.
Publicado: (2020)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study
por: Salzmann, Martin, et al.
Publicado: (2023)

Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors
por: White, Danielle, et al.
Publicado: (2022)

The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
por: Schultz, Nina Haagenrud, et al.
Publicado: (2017)

Determination of Anti-Xa Inhibitor Plasma Concentrations Using a Universal Edoxaban Calibrator
por: Burger, Annika, et al.
Publicado: (2023)

Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
por: Papaj, Katarzyna, et al.
Publicado: (2022)

The Tick-Derived Anticoagulant Madanin Is Processed by Thrombin and Factor Xa
por: Figueiredo, Ana C., et al.
Publicado: (2013)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Application of Molecular Modeling to Development of New Factor Xa Inhibitors
por: Sulimov, Vladimir B., et al.
Publicado: (2015)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

The Development of New Factor Xa Inhibitors Based on Amide Synthesis
por: Tarasov, Dmitry N., et al.
Publicado: (2018)

Less Is More: Microvascular Thrombophylaxis With Factor-Xa Inhibitor Monotherapy
por: Kotha, Vikas S., et al.
Publicado: (2019)

Factor Xa inhibitors: critical considerations for clinical development and testing
por: Becker, Richard C.
Publicado: (2021)

Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
por: Weingarden, Alexa R, et al.
Publicado: (2022)

Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers
por: Sadik, Christian D., et al.
Publicado: (2021)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7n8j3badm6hugo1hvo5ur72sbr